RT Journal Article
T1 Glycosylated BODIPY- Incorporated Pt(II) Metallacycles for Targeted and Synergistic Chemo-Photodynamic Therapy
A1 Durán Sampedro, Gonzalo
A1 Xue, Evelyn .
A1 Evelynoreno-Simoni, Evelyn
A1 Paramio, Celia
A1 Torres, Tomás
A1 Ng, Dennis K. P.
A1 Torre, Gema de la
AB Pt(II)-BODIPY complexes combine the chemotherapeutic activity of Pt(II) with the photocytotoxicity of BODIPYs. Additional conjugation with targeting ligands can boost the uptake by cancer cells that overexpress the corresponding receptors. We describe two Pt(II) triangles, 1 and 2, built with pyridyl BODIPYs functionalized with glucose (3) or triethylene glycol methyl ether (4), respectively. Both 1 and 2 showed higher singlet oxygen quantum yields than 3 and 4, due to the enhanced singlet-to -triplet intersystem crossing. To evaluate the targeting effect of the glycosylated derivative, in vitro experiments were performed using glucose transporter 1 (GLUT1)-positive HT29 and A549 cancer cells, and noncancerous HEK293 cells as control. Both 1 and 2 showed higher cellular uptake than 3 and 4. Specifically, 1 was selective and highly cytotoxic toward HT29 and A549 cells. The synergistic chemo-and photodynamic behavior of the metallacycles was also confirmed. Notably, 1 exhibited superior efficacy toward the cisplatin-resistant R-HepG2 cells. Enhance Cellular Uptake Chemotherapeutic Activity Photoeeneltlaen for PDT
PB American Chemical Society
SN 0022-2623
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/95499
UL https://hdl.handle.net/20.500.14352/95499
LA eng
NO Durán-Sampedro, Gonzalo, et al. «Glycosylated BODIPY- Incorporated Pt(II) Metallacycles for Targeted and Synergistic Chemo-Photodynamic Therapy». Journal of Medicinal Chemistry, vol. 66, n.o 5, marzo de 2023, pp. 3448-59. https://doi.org/10.1021/acs.jmedchem.2c01940.
NO Ministerio de Economía y Competitividad (España)
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 7 abr 2025